Here is the design of a clinical trial:

Official Title: Clinical Assessment of Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma and Airway Microbiome Exploration Research

Included conditions:
- Bronchial Asthma

Study Armgroups:
- {'label': 'Control Group', 'type': 'PLACEBO_COMPARATOR', 'description': '80 participants will take oral therapy of 9.25 g Jia Wei Yang He granule Placebo twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.', 'interventionNames': ['Drug: Jia Wei Yang He granule Placebo']}
- {'label': 'High dose Treatment Group', 'type': 'EXPERIMENTAL', 'description': 'Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 18.5g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.', 'interventionNames': ['Drug: Jia Wei Yang He granule']}
- {'label': 'Low dose Treatment Group', 'type': 'EXPERIMENTAL', 'description': 'Participants in high Jia Wei Yang He formula group will receive Jia Wei Yang He granule 9.25g twice a day for 28 consecutive days and also standard therapy of inhaled corticosteroid or beta2-agonist.', 'interventionNames': ['Drug: Jia Wei Yang He granule']}

Interventions:
- {'type': 'DRUG', 'name': 'Jia Wei Yang He granule', 'description': 'This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time', 'armGroupLabels': ['High dose Treatment Group', 'Low dose Treatment Group'], 'otherNames': ['Jia Wei Yang He Formula']}
- {'type': 'DRUG', 'name': 'Jia Wei Yang He granule Placebo', 'description': 'Made from 1/20 doses which has certain taste, but no therapeutic effect', 'armGroupLabels': ['Control Group'], 'otherNames': ['Placebo']}

Primary Outcomes:
- {'measure': 'Asthma Control Test Score variation', 'description': 'Measured the change from Baseline to the end of treatment', 'timeFrame': 'Baseline and 4 weeks'}

Please estimate the sample size based on the assumption: 
5% significance level, 80% power, and an estimated dropout rate of 20%.
Sample size
        Sample size calculations are based on the primary endpoint (ACT score at 4Â weeks). At the 5% significance level, a total of 64 patients per group is required to achieve 80% power and to determine an increase of 2 points in the ACT score between the high-dose TCM plus usual care group and the placebo plus usual care group, assuming that the standard deviation of the groups is equal to 4 [30]. If the previous hypothesis is rejected, then the difference of 1.5 points in ACT score between the low-dose TCM plus usual care group and the placebo plus usual care group at the 5% significance level is tested. With an estimated dropout rate of 20%, a total of 240 patients is enrolled. If the initial hypothesis is not rejected, subsequent comparison is considered exploratory, and no conclusion is made [31, 32].